Azilsartan CAS: 147403-03-0

CAS NO: 147403-03-0
Azilsartan
Chemical Name: Azilsartan
Molecular Formula: C25H20N4O5
Formula Weight: 456.45
CAS No.: 147403-03-0
Description Review
Description

Azilsartan (CAS: 147403-03-0) is a medication that belongs to the class of angiotensin II receptor blockers (ARBs). It is used to treat hypertension, or high blood pressure, by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict and blood pressure to rise.

Chemical name: 2-Ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid

Molecular formula: C25H20N4O5

Formula weight: 444.45 g/mol

CAS No: 147403-03-0

Top ten keywords from Google:

  1. Azilsartan clinical trials
  2. Angiotensin II receptor blocker
  3. Hypertension
  4. High blood pressure
  5. Cardiovascular health
  6. Renal protection
  7. CAS: 147403-03-0
  8. Stroke prevention
  9. Blood pressure control
  10. ARB

Synonyms:

  • TAK-536
  • Edarbi
  • CAS: 147403-03-0

Health benefits of this product: Azilsartan has demonstrated potential health benefits in several areas, particularly in the treatment of hypertension and cardiovascular disease. It may also have potential benefits for renal protection and stroke prevention, although more research is needed in these areas.

Potential effects: Azilsartan has demonstrated efficacy in several preclinical and clinical studies in reducing blood pressure, improving arterial stiffness, and preventing cardiovascular events in patients with hypertension. It also has potential benefits for renal protection and stroke prevention. Azilsartan works by selectively blocking the angiotensin II receptor, leading to relaxation of blood vessels and reduced blood pressure.

Product mechanism: Azilsartan works by selectively blocking the angiotensin II receptor, which is responsible for causing blood vessels to constrict and blood pressure to rise. By blocking this receptor, azilsartan leads to relaxation of blood vessels, increased blood flow, and reduced blood pressure. It also has potential benefits for reducing inflammation and oxidative stress in the cardiovascular system.

Safety: Azilsartan has been evaluated in several clinical trials involving thousands of participants and has been generally well-tolerated. Rare but potential side effects may include dizziness, headache, diarrhea, and allergic reactions. Patients with kidney disease or liver disease should exercise caution when taking azilsartan, as it may affect these conditions. Pregnant or breastfeeding women should avoid using azilsartan, as it may cause harm to the developing fetus or infant.

Side effects: Common side effects of azilsartan may include dizziness, headache, diarrhea, and fatigue. These symptoms are usually mild or moderate and can be managed with supportive care or dose modifications. Less common but more severe side effects may include hyperkalemia (high potassium levels), hypotension (low blood pressure), and renal impairment, which may require prompt medical intervention. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.

Dosing information: The optimal dose and dosing regimen of azilsartan may vary depending on the patient's condition and treatment goals. In clinical trials, doses ranging from 20 to 80 mg per day have been evaluated for hypertension. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.

Conclusion: Azilsartan (CAS: 147403-03-0) is a medication that belongs to the class of angiotensin II receptor blockers (ARBs) that is used to treat hypertension and prevent cardiovascular events. It works by selectively blocking the angiotensin II receptor, leading to relaxation of blood vessels and reduced blood pressure. Although it has been generally well-tolerated, it may cause some side effects that should be monitored closely. More research is needed to determine its full potential and efficacy in different patient populations and its long-term safety profile

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code